Niagen Bioscience, Inc.

Niagen Bioscience, Inc. is a global bioscience company dedicated to advancing NAD+ (nicotinamide adenine dinucleotide) science and healthy aging research. The company's mission is to enhance healthspan through precision science and innovative NAD+-boosting solutions. Headquartered in Los Angeles, California, Niagen Bioscience was formerly known as ChromaDex Corporation, changing its name in March 2025.

At the core of Niagen Bioscience's offerings is its patented nicotinamide riboside (NR) ingredient, Niagen®, which is clinically proven to increase NAD+ levels. This key ingredient is utilized in the company's consumer supplement line, Tru Niagen®, and its pharmaceutical-grade intravenous (IV) and injectable brand, Niagen Plus™. The company also engages in extensive research and development within the NAD+ space.

In April 2026, Niagen Bioscience announced that Nicotinamide Riboside Chloride (NRCl), the form of nicotinamide riboside in its Niagen ingredient, received a published United States Pharmacopeia (USP) dietary supplement ingredient monograph, establishing quality standards. The company reported strong financial performance for the fourth quarter of 2025, with revenue reaching $33.8 million and earnings per share of $0.05, largely driven by a 21% increase in Tru Niagen sales. Robert Fried serves as the Chief Executive Officer. Niagen Bioscience has also expanded its distribution network through a partnership with OneSpaWorld to offer Niagen IV treatments on luxury cruise ships. To streamline operations and sharpen its focus on NAD+ science, the company sold its ChromaDex Reference Standards business in February 2026.